Hypera Sa S/Adr (HYPMY) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to Ipera Pharma's conference call where we will discuss the earnings for the third quarter of 2025. We have with us Mr. Bruno Oliveira, CEO, and Mr. Ramon Sanchez, CFO and Investor Relations Officer. We would like to inform you that this event is being recorded and you may watch a recording of this video on the company's investor relations website, ri.ipera.com.br. We would like to inform you that all participants are in listen-only mode during the company's presentation. After that, we will begin the questions and answers session when further instructions will be given. Before we continue, we would like to highlight that some of the information in this conference call may include projections and statements about future results. This information is subject to known and unknown risks and uncertainties that may make these expectations not come to pass or to substantially differ from what was expected. We will now hand it over to Mr. Breno Oliveira, who will begin the company's presentation. Go ahead, sir. Good morning and welcome to the third quarter 2025 earnings call. We're going to start on slide three. This is the first quarter after concluding the working capital optimization process that was started last year. And results show that this was implemented successfully. There was no impact to sell out. We conserved profitability and we had significant improvement in our operational cash generation. And we've also maintained investments and shareholder remuneration as planned last year. Sellout went up nearly two percentage points above the market and nearly three percentage points above our growth in the second quarter. Our highlights were influenza medication, painkillers, gastric cardiology, skincare, and hydration. T...